Measurement of disease activity and outcome in atopic dermatitis
- 1 October 1996
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 135 (4), 509-515
- https://doi.org/10.1046/j.1365-2133.1996.d01-1031.x
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical useBritish Journal of Dermatology, 2010
- A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitisJournal of the American Academy of Dermatology, 1994
- A novel therapy for atopic dermatitis with allergen-antibody complexes: A double-blind, placebo-controlled studyJournal of the American Academy of Dermatology, 1993
- Recombinant interferon gamma therapy for atopic dermatitisJournal of the American Academy of Dermatology, 1993
- Topical corticosteroids and Staphylococcus aureus in atopic dermatitisJournal of the American Academy of Dermatology, 1992
- Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitisBritish Journal of Dermatology, 1992
- Guidelines of care for atopic dermatitisJournal of the American Academy of Dermatology, 1992
- Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitisJournal of the American Academy of Dermatology, 1991
- Trial of nedocromil sodium in atopic eczemaBritish Journal of Dermatology, 1990
- Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: A paired-comparison studyJournal of the American Academy of Dermatology, 1990